The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Age Related Macular Degeneration Drug-Global Market Insights and Sales Trends 2025
Synopsis
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
The global Age Related Macular Degeneration Drug market size is expected to reach US$ 11590 million by 2029, growing at a CAGR of 5.9% from 2023 to 2029. The market is mainly driven by the significant applications of Age Related Macular Degeneration Drug in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Age Related Macular Degeneration Drug market. Lucentis, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Eylea segment is estimated at % CAGR for the next seven-year period.
North America is the largest Age Related Macular Degeneration Drug market with about 65% market share. Europe is follower, accounting for about 29% market share.
The key players are Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma etc. Top 3 companies occupied about 79% market share.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Age Related Macular Degeneration Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Age Related Macular Degeneration Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Age Related Macular Degeneration Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Age Related Macular Degeneration Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Age Related Macular Degeneration Drug covered in this report include Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche and Kanghong Pharma, etc.
The global Age Related Macular Degeneration Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma
Global Age Related Macular Degeneration Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Age Related Macular Degeneration Drug market, Segment by Type:
Lucentis
Eylea
Avastin
Others
Global Age Related Macular Degeneration Drug market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Age Related Macular Degeneration Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Age Related Macular Degeneration Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
The global Age Related Macular Degeneration Drug market size is expected to reach US$ 11590 million by 2029, growing at a CAGR of 5.9% from 2023 to 2029. The market is mainly driven by the significant applications of Age Related Macular Degeneration Drug in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Age Related Macular Degeneration Drug market. Lucentis, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Eylea segment is estimated at % CAGR for the next seven-year period.
North America is the largest Age Related Macular Degeneration Drug market with about 65% market share. Europe is follower, accounting for about 29% market share.
The key players are Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma etc. Top 3 companies occupied about 79% market share.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Age Related Macular Degeneration Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Age Related Macular Degeneration Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Age Related Macular Degeneration Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Age Related Macular Degeneration Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Age Related Macular Degeneration Drug covered in this report include Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche and Kanghong Pharma, etc.
The global Age Related Macular Degeneration Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma
Global Age Related Macular Degeneration Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Age Related Macular Degeneration Drug market, Segment by Type:
Lucentis
Eylea
Avastin
Others
Global Age Related Macular Degeneration Drug market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Age Related Macular Degeneration Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Age Related Macular Degeneration Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Age Related Macular Degeneration Drug Market Overview
1.1 Age Related Macular Degeneration Drug Product Overview
1.2 Age Related Macular Degeneration Drug Market Segment by Type
1.2.1 Lucentis
1.2.2 Eylea
1.2.3 Avastin
1.2.4 Others
1.3 Global Age Related Macular Degeneration Drug Market Size by Type
1.3.1 Global Age Related Macular Degeneration Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Age Related Macular Degeneration Drug Historic Market Size Review by Type (2018-2023)
1.3.3 Global Age Related Macular Degeneration Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Age Related Macular Degeneration Drug Sales Breakdown by Type (2018-2023)
1.4.2 Europe Age Related Macular Degeneration Drug Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Age Related Macular Degeneration Drug Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Age Related Macular Degeneration Drug Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Age Related Macular Degeneration Drug Sales Breakdown by Type (2018-2023)
2 Global Age Related Macular Degeneration Drug Market Competition by Company
2.1 Global Top Players by Age Related Macular Degeneration Drug Sales (2018-2023)
2.2 Global Top Players by Age Related Macular Degeneration Drug Revenue (2018-2023)
2.3 Global Top Players by Age Related Macular Degeneration Drug Price (2018-2023)
2.4 Global Top Manufacturers Age Related Macular Degeneration Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Age Related Macular Degeneration Drug Market Competitive Situation and Trends
2.5.1 Age Related Macular Degeneration Drug Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Age Related Macular Degeneration Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Age Related Macular Degeneration Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Age Related Macular Degeneration Drug Market
2.8 Key Manufacturers Age Related Macular Degeneration Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Age Related Macular Degeneration Drug Status and Outlook by Region
3.1 Global Age Related Macular Degeneration Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Age Related Macular Degeneration Drug Historic Market Size by Region
3.2.1 Global Age Related Macular Degeneration Drug Sales in Volume by Region (2018-2023)
3.2.2 Global Age Related Macular Degeneration Drug Sales in Value by Region (2018-2023)
3.2.3 Global Age Related Macular Degeneration Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Age Related Macular Degeneration Drug Forecasted Market Size by Region
3.3.1 Global Age Related Macular Degeneration Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Age Related Macular Degeneration Drug Sales in Value by Region (2024-2029)
3.3.3 Global Age Related Macular Degeneration Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Age Related Macular Degeneration Drug by Application
4.1 Age Related Macular Degeneration Drug Market Segment by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Others
4.2 Global Age Related Macular Degeneration Drug Market Size by Application
4.2.1 Global Age Related Macular Degeneration Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Age Related Macular Degeneration Drug Historic Market Size Review by Application (2018-2023)
4.2.3 Global Age Related Macular Degeneration Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Age Related Macular Degeneration Drug Sales Breakdown by Application (2018-2023)
4.3.2 Europe Age Related Macular Degeneration Drug Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Age Related Macular Degeneration Drug Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Age Related Macular Degeneration Drug Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Age Related Macular Degeneration Drug Sales Breakdown by Application (2018-2023)
5 North America Age Related Macular Degeneration Drug by Country
5.1 North America Age Related Macular Degeneration Drug Historic Market Size by Country
5.1.1 North America Age Related Macular Degeneration Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Age Related Macular Degeneration Drug Sales in Volume by Country (2018-2023)
5.1.3 North America Age Related Macular Degeneration Drug Sales in Value by Country (2018-2023)
5.2 North America Age Related Macular Degeneration Drug Forecasted Market Size by Country
5.2.1 North America Age Related Macular Degeneration Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Age Related Macular Degeneration Drug Sales in Value by Country (2024-2029)
6 Europe Age Related Macular Degeneration Drug by Country
6.1 Europe Age Related Macular Degeneration Drug Historic Market Size by Country
6.1.1 Europe Age Related Macular Degeneration Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Age Related Macular Degeneration Drug Sales in Volume by Country (2018-2023)
6.1.3 Europe Age Related Macular Degeneration Drug Sales in Value by Country (2018-2023)
6.2 Europe Age Related Macular Degeneration Drug Forecasted Market Size by Country
6.2.1 Europe Age Related Macular Degeneration Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Age Related Macular Degeneration Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Age Related Macular Degeneration Drug by Region
7.1 Asia-Pacific Age Related Macular Degeneration Drug Historic Market Size by Region
7.1.1 Asia-Pacific Age Related Macular Degeneration Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Age Related Macular Degeneration Drug Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Age Related Macular Degeneration Drug Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Age Related Macular Degeneration Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Age Related Macular Degeneration Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Age Related Macular Degeneration Drug Sales in Value by Region (2024-2029)
8 Latin America Age Related Macular Degeneration Drug by Country
8.1 Latin America Age Related Macular Degeneration Drug Historic Market Size by Country
8.1.1 Latin America Age Related Macular Degeneration Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Age Related Macular Degeneration Drug Sales in Volume by Country (2018-2023)
8.1.3 Latin America Age Related Macular Degeneration Drug Sales in Value by Country (2018-2023)
8.2 Latin America Age Related Macular Degeneration Drug Forecasted Market Size by Country
8.2.1 Latin America Age Related Macular Degeneration Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Age Related Macular Degeneration Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Age Related Macular Degeneration Drug by Country
9.1 Middle East and Africa Age Related Macular Degeneration Drug Historic Market Size by Country
9.1.1 Middle East and Africa Age Related Macular Degeneration Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Age Related Macular Degeneration Drug Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Age Related Macular Degeneration Drug Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Age Related Macular Degeneration Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Age Related Macular Degeneration Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Age Related Macular Degeneration Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Regeneron Pharmaceuticals
10.1.1 Regeneron Pharmaceuticals Company Information
10.1.2 Regeneron Pharmaceuticals Introduction and Business Overview
10.1.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Products Offered
10.1.5 Regeneron Pharmaceuticals Recent Development
10.2 Bayer HealthCare
10.2.1 Bayer HealthCare Company Information
10.2.2 Bayer HealthCare Introduction and Business Overview
10.2.3 Bayer HealthCare Age Related Macular Degeneration Drug Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Bayer HealthCare Age Related Macular Degeneration Drug Products Offered
10.2.5 Bayer HealthCare Recent Development
10.3 Novartis
10.3.1 Novartis Company Information
10.3.2 Novartis Introduction and Business Overview
10.3.3 Novartis Age Related Macular Degeneration Drug Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Novartis Age Related Macular Degeneration Drug Products Offered
10.3.5 Novartis Recent Development
10.4 Roche
10.4.1 Roche Company Information
10.4.2 Roche Introduction and Business Overview
10.4.3 Roche Age Related Macular Degeneration Drug Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Roche Age Related Macular Degeneration Drug Products Offered
10.4.5 Roche Recent Development
10.5 Kanghong Pharma
10.5.1 Kanghong Pharma Company Information
10.5.2 Kanghong Pharma Introduction and Business Overview
10.5.3 Kanghong Pharma Age Related Macular Degeneration Drug Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Kanghong Pharma Age Related Macular Degeneration Drug Products Offered
10.5.5 Kanghong Pharma Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Age Related Macular Degeneration Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Age Related Macular Degeneration Drug Industrial Chain Analysis
11.4 Age Related Macular Degeneration Drug Market Dynamics
11.4.1 Age Related Macular Degeneration Drug Industry Trends
11.4.2 Age Related Macular Degeneration Drug Market Drivers
11.4.3 Age Related Macular Degeneration Drug Market Challenges
11.4.4 Age Related Macular Degeneration Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Age Related Macular Degeneration Drug Distributors
12.3 Age Related Macular Degeneration Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
